Clearside raises $20M; Egalet nixes Shionogi deal;

@FierceBiotech: Pfizer is shuttering another U.K. R&D outpost, ditching 120 jobs. Article | Follow @FierceBiotech

@JohnCFierce: Lilly pulls the plug on a massive insulin project in a blow to its diabetes pipeline. Story | Follow @JohnCFierce

@DamianFierce: this is good SEO. Link | Follow @DamianFierce

> Clearside Biomedical closed a $20 million Series C financing to support its work on micro-injected treatments for back-of-the-eye diseases. News

> Novo Nordisk ($NVO) filed for European approval for a fast-acting version of its insulin NovoLog. More

> Egalet ($EGLT) terminated its collaboration with Shionogi, regaining the rights to a Phase I hydrocodone treatment designed to discourage abuse. Release

Medical Device News

@FierceMedDev: Dx Digest: Report | Follow @FierceMedDev

@VarunSaxena2: I've never seen a team invent so many ways to lose as the Detroit Lions! I knew it was coming! Unsure of call but it's the Lions after all. | Follow @VarunSaxena2

@EmilyWFierce: Google Life Sciences CMO opens up about research plans. Story | Follow @EmilyWFierce

> NIH funds a trio of robots to improve health, life quality for the disabled. Report

> Troubled Insulet recalling additional 18 lots of wearable insulin pump due to needle failure. More

Pharma News

@FiercePharma: #ICYMI yesterday: $TEVA to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters. Story | Follow @FiercePharma

@CarlyHFierce: Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s. Story | Follow @CarlyHFierce

> If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says. More

> Cancer drug prices vary across the globe as countries strike deals with Big Pharma: Study. Report

> Sun to launch copy of Novartis' best-selling drug Gleevec Feb. 1. Story

Suggested Articles

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.